An ETH spin-off aims to bring gene scissors to the clinic
Thanks to CRISPR/Cas technology, researchers can precisely edit genetic material to treat hereditary diseases. To achieve this, they need to identify undesirable cuts in the genome at an early juncture. Pioneer Fellow Lilly van de Venn is developing exactly such testing methods.